{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=autologous+dendritic+cells&page=7",
    "query": {
      "intervention": "autologous dendritic cells",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 195,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=autologous+dendritic+cells&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=autologous+dendritic+cells&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T01:11:09.622Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00056758",
      "title": "HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Autologous Dendritic Cell HIV Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2003-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-08-27",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056758"
    },
    {
      "nct_id": "NCT02366728",
      "title": "DC Migration Study for Newly-Diagnosed GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Astrocytoma, Grade IV",
        "Giant Cell Glioblastoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Unpulsed DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "111In-labeled DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-10-12",
      "completion_date": "2020-10-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02366728"
    },
    {
      "nct_id": "NCT02033616",
      "title": "Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Ovarian Carcinoma",
        "Stage IV Ovarian Carcinoma",
        "Fallopian Tube Carcinoma",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "AVOVA-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aivita Biomedical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 99,
      "start_date": "2017-11-18",
      "completion_date": "2023-03",
      "has_results": false,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 6,
      "location_summary": "Burbank, California • La Jolla, California • Newport Beach, California + 2 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02033616"
    },
    {
      "nct_id": "NCT00363467",
      "title": "Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Stem cell reinfusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "56 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "56 Years to 74 Years"
      },
      "enrollment_count": 3,
      "start_date": "2006-05",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00363467"
    },
    {
      "nct_id": "NCT00005992",
      "title": "Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "PSA prostate cancer vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous dendritic cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": null,
      "start_date": "2000-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005992"
    },
    {
      "nct_id": "NCT00923351",
      "title": "Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Sarcoma",
        "Rhabdomyosarcoma-Embryonal",
        "Rhabdomyosarcoma- Alveolar",
        "Neuroectodermal Tumors, Primitive, Peripheral"
      ],
      "interventions": [
        {
          "name": "Tumor Purged/CD25 Depleted Lymphocytes",
          "type": "DRUG"
        },
        {
          "name": "Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rhIL-7",
          "type": "DRUG"
        },
        {
          "name": "Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Months",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "19 Months to 35 Years"
      },
      "enrollment_count": 44,
      "start_date": "2007-06-02",
      "completion_date": "2018-05-15",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923351"
    },
    {
      "nct_id": "NCT02479230",
      "title": "Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Joseph Baar, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2015-07-17",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2022-11-22",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02479230"
    },
    {
      "nct_id": "NCT07374029",
      "title": "Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia, in Relapse"
      ],
      "interventions": [
        {
          "name": "DC/AML Fusion Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "David Avigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2026-02-12",
      "completion_date": "2030-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07374029"
    },
    {
      "nct_id": "NCT00323115",
      "title": "Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Autologous Dendritic Cell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Dendritic Cell Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2006-05",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323115"
    },
    {
      "nct_id": "NCT06253494",
      "title": "Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer",
        "Cancer of Endometrium",
        "Carcinoma of Endometrium",
        "Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "AdHER2DC vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "N-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "PATHWAY HER2 (4B5) assay",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-05-14",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-19T01:11:09.622Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06253494"
    }
  ]
}